Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Daiichi Sankyo Company, Limited    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report  
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (JPY)
Sales 2020 965 B
EBIT 2020 124 B
Net income 2020 91 168 M
Finance 2020 327 B
Yield 2020 1,03%
Sales 2021 990 B
EBIT 2021 114 B
Net income 2021 84 216 M
Finance 2021 413 B
Yield 2021 1,09%
P/E ratio 2020 48,5x
P/E ratio 2021 52,2x
EV / Sales2020 4,24x
EV / Sales2021 4,04x
Capitalization 4 415 B
More Financials
Company
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows: - sale of medicines (99.7%): prescription medicines (93% of net sales) and OTC medicines (7%) primarily for the treatment of thrombotic disorders,... 
Sector
Pharmaceuticals
Calendar
10/31Earnings Release
More about the company
Surperformance© ratings of Daiichi Sankyo Company, Li
Trading Rating : Investor Rating :
More Ratings
Latest news on DAIICHI SANKYO COMPANY, LI
10/16DAIICHI SANKYO : Announces Transfer from Astellas Pharma of Three Products in As..
AQ
09/27Kansai Electric president apologises for payments scandal
RE
09/27DAIICHI SANKYO COMPANY, LIMITED : Ex-dividend day for interim dividend
FA
09/18Mitsubishi Tanabe Pharma and Daiichi Sankyo announce alliance for ALS treatme..
AQ
09/17Trial of Tepco executives over Japan's Fukushima disaster heads to conclusion
RE
09/12DAIICHI SANKYO : Announces Launch of Oxycodone Extended Release Tablets NX 'Daii..
AQ
09/04AstraZeneca's Tagrisso gets China OK for type of lung cancer
RE
08/23GSK builds oncology pipeline as drug shown to help myeloma patients
RE
08/12Influenza Vaccines Market is Expected to Surpass USD 6 billion by 2025 | Key ..
AQ
08/08MCKESSON : TURALIO FDA Approved Treatment of TGCT, Available at Biologics by McK..
AQ
08/05DAIICHI SANKYO : FDA Approves Daiichi Sankyo's TURALIO for the Treatment of Sele..
AQ
07/31DAIICHI SANKYO COMPANY, LIMITED : Slide show Q1 results
CO
07/31DAIICHI SANKYO COMPANY, LIMITED : 1st quarter results
CO
07/25AstraZeneca raises sales forecast after second quarter cancer drug, China boo..
RE
06/26GENERAL ELECTRIC : Daiichi Sankyo to transfer marketing authorization rights for..
AQ
More news
News in other languages on DAIICHI SANKYO COMPANY, LI
10/18ASTRAZENECA : examen prioritaire pour un traitement
09/27DAIICHI SANKYO COMPANY, LIMITED : Ex-dividend day for interim dividend
09/19'Tsunami unvorhersehbar' - Freispruch für Ex-Atommanager in Japan
09/19ACCIDENT DE FUKUSHIMA : 3 ex-dirigeants de Tepco acquittés
07/31Aktien Schweiz Schluss: Finanzwerte und Schwergewichte verhelfen SMI zu Kursp..
More news
Analyst Recommendations on DAIICHI SANKYO COMPANY, LI
More recommendations
Sector news : Pharmaceuticals - NEC
02:48aJ&J Recalls Baby Powder For Asbestos -- WSJ
DJ
10/18More Money Demanded in Opioid Settlement Talks -- Update
DJ
10/18More Money Demanded in Opioid Settlement Talks
DJ
10/18JOHNSON & JOHNSON : J&J Recalls Baby Powder on Asbestos Concern -- 2nd Update
DJ
10/18Sanofi pulls Zantac from U.S. and Canada after carcinogen found
RE
More sector news : Pharmaceuticals - NEC
Technical analysis trends DAIICHI SANKYO COMPANY, LI
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 7 750,00  JPY
Last Close Price 6 814,00  JPY
Spread / Highest target 46,8%
Spread / Average Target 13,7%
Spread / Lowest Target -19,3%
EPS Revisions
Managers
NameTitle
Joji Nakayama Chairman & Chief Executive Officer
Sunao Manabe President, COO & Representative Director
Toshiaki Sai CFO, Representative Director & Vice President
Junichi Koga Senior Managing Executive Officer, Global Head-R&D
Katsumi Fujimoto Director
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY, LIMITED98.95%40 683
JOHNSON & JOHNSON-1.05%337 021
ROCHE HOLDING AG18.49%250 869
MERCK AND COMPANY10.82%216 813
PFIZER-16.47%201 662
NOVARTIS15.95%198 751